Developed RenMab Mouse, a fully human antibody mouse model; Closed D-round funding in July
2019.4
Beijing and Haimen Phase II animal facility is under construction
2018.4
Received C-round funding from CMB International Capital Corporation Limited, SDIC Venture Capital, 3E Bioventures, Cowin Capital Group and Oriza Holdings
2018.2
Boston and Shanghai sites opened for business
2016
Haimen Animal Center began operations; AAALAC accreditation earned; Antibody Discovery Service Platform established; B-NDG™ and a comprehensive variety of humanized immune checkpoint mice were supplied to clients
2015
Established preclinical services platform; Raised B-round funding from SDIC Venture Capital and BioVeda China Fund
2014
Developed B-NDG™ mice (highly immune deficient) and B-hPD-1, the first humanized immune-checkpoint mouse model
2011
1st customized gene targeted mouse line delivered
2009
Beijng Biocytogen Co., Ltd (Headquarters) established